National Bank Reaffirms Their Buy Rating on Lundin Mining (LUNMF)
National Bank analyst Shane Nagle maintained a Buy rating on Lundin Mining (LUNMF – Research Report) today and set a price target of C$16.50. The company's shares closed today at $10.05.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nagle covers the Basic Materials sector, focusing on stocks such as Agnico Eagle, Franco-Nevada, and Kinross Gold. According to TipRanks, Nagle has an average return of 21.2% and a 70.04% success rate on recommended stocks.
Currently, the analyst consensus on Lundin Mining is a Moderate Buy with an average price target of $11.06, a 10.05% upside from current levels. In a report released on June 18, BMO Capital also maintained a Buy rating on the stock with a C$16.00 price target.
LUNMF market cap is currently $8.52B and has a P/E ratio of -74.81.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LUNMF in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting' data
H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug's 'highly differentiated mechanism of action' compared to currently approved therapies, H.C. Wainwright believes rezpeg 'has the potential to reshape the treatment landscape' for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a 'paradigm-shifting' atopic dermatitis drug 'has arrived.' The stock in midday trading is up 134%, or $12.82, to $22.36. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on NKTR: Disclaimer & DisclosureReport an Issue Nektar price target raised to $120 from $6.50 at H.C. Wainwright Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? Nektar jumps 130% to $21.90 after atopic dermatitis study success Nektar Therapeutics Announces Positive Phase 2b Trial Results Nektar's rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
No Ad Comm ‘not necessarily positive' for Capricor, says Roth Capital
Roth Capital analyst Boobalan Pachaiyappan tells investors in a research note that the FDA's intention not to require an Ad Comm 'at this time' for deramiocel for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy 'may not necessarily be positive news,' and that it believes a promissory Ad Comm meeting would be positive, as a potential positive Ad Comm panel vote would put pressure on the new leadership to approve deramiocel in its current form. The firm reiterates a Buy rating and $31 price target on Capricor shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CAPR: Disclaimer & DisclosureReport an Issue Capricor's deramiocel moves ahead without AdCom, says H.C. Wainwright HHS spokesperson tells Reuters FDA 'actively re-evaluating' Capricor AdCom Capricor Therapeutics provides regulatory update on Deramiocel BLA Roth says 'excessive' Capricor selloff due to 'investor overreaction' Capricor selloff brings buying opportunity, says H.C. Wainwright Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Diabetes stocks rally after RFK comments on HHS campaign
Sarah Karlin-Smith of Pink Sheet reported via X: 'RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing 'wearable' in 4 years.' Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on TNDM: Disclaimer & DisclosureReport an Issue Cisco upgraded, CoreWeave downgraded: Wall Street's top analyst calls Tandem Diabetes initiated with a Hold at Truist Tandem Diabetes announces agreement with Abbott to develop diabetes solutions Tandem Diabetes Care: Strategic Initiatives and Product Launches Drive Long-Term Growth Potential Balanced Outlook on Tandem Diabetes Care: Growth Opportunities Amid Strategic Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
